Endovia Health Sciences, Inc. (EDVA)
NYSEAMERICAN: EDVA · Real-Time Price · USD
0.2492
+0.0052 (2.13%)
At close: Sep 11, 2026, 4:00 PM EDT
0.2494
+0.0002 (0.08%)
After-hours: Sep 11, 2026, 8:00 PM EDT
Endovia Health Sciences Revenue
Endovia Health Sciences had revenue of $-2.51M in the twelve months ending June 30, 2026. In the year 2025, Endovia Health Sciences had annual revenue of $73.07K, down -90.88%.
Revenue (ttm)
$-2.51M
Revenue Growth
-90.88%
P/S Ratio
49.80
Revenue / Employee
$16,045
Employees
2
Market Cap
1.60M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.07K | -728.21K | -90.88% |
| Dec 31, 2024 | 801.27K | -18.05M | -95.75% |
| Dec 31, 2023 | 18.85M | 762.67K | 4.22% |
| Dec 31, 2022 | 18.09M | 6.77M | 59.84% |
| Dec 31, 2021 | 11.32M | 9.02M | 391.97% |
| Dec 31, 2020 | 2.30M | 2.28M | 11,182.32% |
| Dec 31, 2019 | 20.39K | -1.29M | -98.44% |
| Dec 31, 2018 | 1.31M | 413.83K | 46.22% |
| Dec 31, 2017 | 895.35K | -116.95K | -11.55% |
| Dec 31, 2016 | 1.01M | 114.95K | 12.81% |
| Dec 31, 2015 | 897.34K | 291.44K | 48.10% |
| Dec 31, 2014 | 605.91K | 130.65K | 27.49% |
| Dec 31, 2013 | 475.25K | 166.52K | 53.94% |
| Dec 31, 2012 | 308.73K | 24.90K | 8.77% |
| Dec 31, 2011 | 283.83K | -48.61K | -14.62% |
| Dec 31, 2010 | 332.43K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| Curis | 4.31M |
| Decoy Therapeutics | 227.63K |
| Biodexa Pharmaceuticals | 104.90K |
| Virax Biolabs Group | 12.42K |
| Valion Bio | -86.00K |
EDVA News
- 12 days ago - Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline - GlobeNewsWire
- 18 days ago - Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program - GlobeNewsWire
- 22 days ago - Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday - GlobeNewsWire
- 23 days ago - Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences - GlobeNewsWire
- 4 weeks ago - Splash Beverage Group to Rebrand as Endovia Health Sciences - GlobeNewsWire
- 5 weeks ago - Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway - GlobeNewsWire
- 6 weeks ago - Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program - GlobeNewsWire
- 2 months ago - Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation - GlobeNewsWire